Att B - 60 day FRN

33303

Federal Register / Vol. 76, No. 110 / Wednesday, June 8, 2011 / Notices
based tobacco control policies and
interventions including telephone
quitlines to increase tobacco use
cessation.
Tobacco control is also a top priority
for federally-funded cancer control
programs. Currently, 65 organizations
are funded through CDC’s National
Comprehensive Cancer Control Program
(NCCCP): all 50 states, the District of
Columbia, seven tribes/tribal
organizations, and seven U.S.
territories/Pacific Island Jurisdictions.
NCCCP grantees are charged with
establishing NCCCP coalitions,
assessing the burden of cancer, and
developing and implementing
comprehensive cancer control (CCC)
plans. The CCC plans address
interventions across the cancer
continuum from primary prevention to
treatment and survivorship. The NCCCP
is managed by CDC’s Division of Cancer
Prevention and Control (DCPC).
CDC recognizes the need for increased
collaboration between CCCs and TCPs.
Toward this end, CDC plans to conduct
a study of current partnership efforts
involving NCCCP awardees and NTCP
awardees. Information will be collected

to improve understanding of the ways in
which CCCs and TCPs may collaborate
to address cancer and tobacco control,
and how these programs utilize their
respective networks to cross-promote
activities. The Partnership Study will be
conducted in seven states that: (1) Are
funded through both the NCCCP and the
NTCP and (2) have an established
relationship between the two programs.
Respondents for the Study of
Comprehensive Cancer Control and
Tobacco Control Program Partnerships
will be state health department leaders,
CCC and TCP staff (e.g., program
directors, evaluation specialists, media
specialists, quitline coordinators), and
other stakeholders, such as coalition
members. Information will be collected
through in-person interviews involving
approximately 15 respondents in each
state. Respondents will be asked about
key aspects of their program’s structure
and activities, including efforts to
coordinate across the CCC–TCP
structure and facilitators and/or barriers
influencing CCC–TCP collaborations.
The questions in each interview will be
customized depending on the
respondent’s role. Each interview will

last approximately 45 minutes to one
hour.
CDC plans to request OMB approval
for one year. The information to be
collected in the Partnership Study will
be used to develop examples of
successful strategies used by selected
CCCs and TCPs to cross-collaborate and
cross-promote programs/services, and to
identify new areas of potential
collaboration that may be shared with
CDC, other federal agencies, and other
CCC and TCP states for replication.
The Partnership Study will
complement and extend the usefulness
of results to be obtained in a companion
study titled ‘‘Comparing the
Effectiveness of Traditional EvidenceBased Tobacco Cessation Interventions
to Newer and Innovative Interventions
Used by Comprehensive Cancer Control
Programs.’’ Additional information
about the companion project will be
published in a separate Federal Register
Notice. Both studies will be funded
through the American Recovery and
Reinvestment Act of 2009 (ARRA).
There are no costs to respondents other
than their time.

ESTIMATED ANNUALIZED BURDEN HOURS
Form name

State Health Department Leadership

Interview Guide for Health Department Leadership.
Site Visit Preparation .......................
49 .....................................................
Site Visit Preparation .......................
49 .....................................................
...........................................................

CCC Programs ..................................
Interview Guide for CCCs .................
Tobacco Control Programs ...............
Interview Guide for TCPs .................
Total ...........................................

Dated: June 1, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–14145 Filed 6–7–11; 8:45 am]
BILLING CODE;P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention

sroberts on DSK5SPTVN1PROD with NOTICES

[60Day-11–11GU]

Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on

VerDate Mar<15>2010

21:51 Jun 07, 2011

Jkt 223001

Frm 00113

Fmt 4703

Total burden
(in hours)

7

1

45/60

5

7
1
7
1
........................

1
1
1
1
........................

45/60
49
45/60
49
113

5

proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Daniel Holcomb, CDC
Reports Clearance Officer, 1600 Clifton
Road, MS–D74, Atlanta, GA 30333 or
send an e-mail to [email protected].
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the

PO 00000

Average burden per response
(in hours)

No. of responses per
respondent

Total number
of respondents

Type of respondent

Sfmt 4703

burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
Survey of Rapid Influenza Diagnostic
Test (RIDT) Practices in Clinical
Laboratories—New—the Office of
Surveillance, Epidemiology, and
Laboratory Services (OSELS), Centers
for Disease Control and Prevention
(CDC).
Background and Brief Description
The Survey of Rapid Influenza
Diagnostic Testing Practices in Clinical
Laboratories is a national systematic
study investigating rapid influenza
diagnostic testing practices in clinical

E:\FR\FM\08JNN1.SGM

08JNN1

5

33304

Federal Register / Vol. 76, No. 110 / Wednesday, June 8, 2011 / Notices

laboratories. The survey will be funded
in full by the Office of Surveillance,
Epidemiology, and Laboratory Services
(OSELS) of the Centers for Disease
Control and Prevention (CDC). Influenza
epidemics usually cause an average
more than 200,000 hospitalizations and
36,000 deaths per year in the U.S.
Respiratory illnesses caused by
influenza viruses are not easily
differentiated from other respiratory
infections based solely on symptoms.
Also influenza viruses may adversely
affect different subpopulations. The
effective use of rapid influenza
diagnostic testing practices is an
important component of the differential
diagnosis of influenza-like-illness in
both inpatient and outpatient treatment
facilities. Test results are used for
making decisions about antiviral vs.
antibiotic use, and in making admission
or discharge decisions. In many cases,
rapid influenza tests are the only tests
that can provide results while the
patient is still present in the facility.
Thus, the appropriate use of the tests,
and interpretation of test results is
critical to the treatment and control of
influenza. More than a dozen rapid tests

emergency departments and treatment
facilities and health departments, and
what quality assurance practices are
used will guide future efforts of the CDC
to develop appropriate influenza testing
guidelines and sector-specific training
materials for clinicians and improve
health outcomes of the American
public.
The survey covers basic laboratory
demographic characteristics, specimen
collection and processing, testing
practices, reporting of results to
emergency departments and other
treatment facilities, reporting results to
health departments, quality assurance
practices, and methods of receiving
updated influenza-related information.
The majority of the questions request
information about laboratory influenza
testing practices.
To date, no systematic study has been
conducted to investigate how
laboratories use these tests, how they
report results, or how they interact with
outpatient treatment facilities. The
survey will be conducted on a national
sample of clinical laboratories. There
are no costs to respondents except their
time.

have been approved by the U.S. Food
and Drug Administration and are in
widespread use. The reliability of rapid
influenza tests is influenced by the
individual test product used and the
setting. Reported sensitivities range
from 10–75%; while the median
specificities reported are 90–95%. Other
factors influencing accuracy are the
stage (or duration) of illness when the
diagnostic specimen is collected, type
and adequacy of the specimen collected,
variability in user technique for
specimen collection or assay
performance, and disease activity in the
community. Given these and other
collective findings, it is imperative for
public health and for response planning
that CDC develops sector-specific
guidance and effective outreach to the
clinicians on appropriate use of RIDT in
their practices.
Previous studies by CDC of outpatient
facilities showed that clinical
laboratories usually perform the rapid
tests for emergency departments, and
provide results for both inpatient and
outpatient treatment. Thus,
understanding the use of rapid
influenza testing in clinical laboratories,
how the laboratories report results to

ESTIMATED ANNUALIZED BURDEN HOURS
No. of
responses per
respondent

Avg. burden
per response
(in hrs)

Total burden
(in hrs)

Form name

Clinical Laboratory Supervisors ........

Survey of Rapid Influenza Diagnostic Test Practices in Clinical
Laboratories.

600

1

30/60

300

Total ...........................................

..........................................................

........................

........................

........................

300

Dated: June 1, 2011.
Daniel Holcomb,
Reports Clearance Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2011–14147 Filed 6–7–11; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
sroberts on DSK5SPTVN1PROD with NOTICES

No. of
respondents

Type of respondents

The meeting announced below
concerns Strategies to Improve
Vaccination Coverage of Children in
Child Care Centers (CCCs) and
Preschools, Funding Opportunity
Announcement (FOA) IP11–006;
Strategies to Increase Health Care

VerDate Mar<15>2010

21:51 Jun 07, 2011

Jkt 223001

Providers Use of Population-Based
Immunization Information Systems,
FOA IP11–008; Effectiveness in an
Intervention to Promote a Targeted
Vaccination program in the
Obstetrician-Gynecologist Setting, FOA
IP11–009; initial review.
Correction: The notice was published
in the Federal Register on April 29,
2011, Volume 76, Number 83, Pages
24031. The place should read as
follows:
Place: Holiday Inn Decatur
Conference Center, 130 Clairemont
Avenue, Decatur, Georgia 30030,
Telephone: (404)371–0204.
Contact Person for More Information:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road, NE., Mailstop E00,
Atlanta, Georgia 30333, Telephone:
(404) 498–2293.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register

PO 00000

Frm 00114

Fmt 4703

Sfmt 9990

notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Dated: May 27, 2011.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2011–14202 Filed 6–7–11; 8:45 am]
BILLING CODE 4163–18–P

E:\FR\FM\08JNN1.SGM

08JNN1